Rahma Udu1, Job Oyweri1, Jeremiah Gathirwa2. 1. Department of Pure and Applied Sciences, School of Applied & Health Sciences, Technical University of Mombasa, P.O. Box 90420-80100, Mombasa, Kenya. 2. Centre for Traditional Medicine and Drug Research, Kenya Medical Research Institute, P.O. Box 54840-0002, Nairobi, Kenya.
Abstract
BACKGROUND: Chemotherapy plays a crucial role in malaria control. However, the main obstacle to treatment has been the rise of parasite resistance to most antimalarial drugs. Artemisinin-based combination therapies (ACTs) remain the most effective antimalarial medicines available today. However, malaria parasite tolerance to ACTs is now increasingly prevalent especially in Southeast Asia presenting the danger of the spread of ACTs resistance to other parts of the world. Consequently, this creates the need for alternative effective antimalarials. Therefore, this study sought out to determine antimalarial potential, safety, and resistance development of the extracts in a mouse model. METHOD: Methanolic and ethyl acetate extracts were obtained by solvent extraction. The extracts were assayed for acute toxicity in vivo. Additionally, the two extracts were evaluated for antimalarial activity in vivo against Plasmodium berghei ANKA strain by the 4-day suppressive test at 500, 250, and 125 mg/kg/day. Packed cell volume was evaluated to determine anemia manifestation. Finally, continuous drug pressure experiment at 500 mg/kg and DNA amplification via PCR were conducted. The amplicons underwent through Sanger sequencing. RESULTS: There was no toxicity realized in the animals at 2000 mg/kg. Importantly, high parasitemia suppression of 75.52% and 75.30% using a dose of 500 mg/kg of methanolic and ethyl acetate extracts, respectively, was noted. The extracts were able to reverse packed cell volume reduction. Nigella sativa-resistant phenotype was selected as delayed parasite clearance. However, there was no change in the nucleotide sequences of PbMDR1 and PbCRT genes. CONCLUSION: The results provide room for future exploitation of the plant as an antimalarial.
BACKGROUND: Chemotherapy plays a crucial role in malaria control. However, the main obstacle to treatment has been the rise of parasite resistance to most antimalarial drugs. Artemisinin-based combination therapies (ACTs) remain the most effective antimalarial medicines available today. However, malaria parasite tolerance to ACTs is now increasingly prevalent especially in Southeast Asia presenting the danger of the spread of ACTs resistance to other parts of the world. Consequently, this creates the need for alternative effective antimalarials. Therefore, this study sought out to determine antimalarial potential, safety, and resistance development of the extracts in a mouse model. METHOD: Methanolic and ethyl acetate extracts were obtained by solvent extraction. The extracts were assayed for acute toxicity in vivo. Additionally, the two extracts were evaluated for antimalarial activity in vivo against Plasmodium berghei ANKA strain by the 4-day suppressive test at 500, 250, and 125 mg/kg/day. Packed cell volume was evaluated to determine anemia manifestation. Finally, continuous drug pressure experiment at 500 mg/kg and DNA amplification via PCR were conducted. The amplicons underwent through Sanger sequencing. RESULTS: There was no toxicity realized in the animals at 2000 mg/kg. Importantly, high parasitemia suppression of 75.52% and 75.30% using a dose of 500 mg/kg of methanolic and ethyl acetate extracts, respectively, was noted. The extracts were able to reverse packed cell volume reduction. Nigella sativa-resistant phenotype was selected as delayed parasite clearance. However, there was no change in the nucleotide sequences of PbMDR1 and PbCRT genes. CONCLUSION: The results provide room for future exploitation of the plant as an antimalarial.
Authors: J W Gathirwa; G M Rukunga; E N M Njagi; S A Omar; P G Mwitari; A N Guantai; F M Tolo; C W Kimani; C N Muthaura; P G Kirira; T N Ndunda; G Amalemba; G M Mungai; I O Ndiege Journal: J Ethnopharmacol Date: 2007-09-29 Impact factor: 4.360
Authors: Ebtesam Saad Al-Sheddi; Nida Nayyar Farshori; Mai Mohammad Al-Oqail; Javed Musarrat; Abdulaziz Ali Al-Khedhairy; Maqsood Ahmed Siddiqui Journal: Asian Pac J Cancer Prev Date: 2014
Authors: L Tona; K Mesia; N P Ngimbi; B Chrimwami; K Cimanga; T de Bruyne; S Apers; N Hermans; J Totte; L Pieters; A J Vlietinck Journal: Ann Trop Med Parasitol Date: 2001-01
Authors: Alvaro José Romanha; Solange Lisboa de Castro; Maria de Nazaré Correia Soeiro; Joseli Lannes-Vieira; Isabela Ribeiro; André Talvani; Bernadette Bourdin; Bethania Blum; Bianca Olivieri; Carlos Zani; Carmenza Spadafora; Egler Chiari; Eric Chatelain; Gabriela Chaves; José Eduardo Calzada; Juan Manuel Bustamante; Lucio H Freitas-Junior; Luz I Romero; Maria Terezinha Bahia; Michel Lotrowska; Milena Soares; Sonia Gumes Andrade; Tanya Armstrong; Wim Degrave; Zilton de Araújo Andrade Journal: Mem Inst Oswaldo Cruz Date: 2010-03 Impact factor: 2.743
Authors: Suci Nuralitha; Josephine E Siregar; Din Syafruddin; Jessica Roelands; Jan Verhoef; Andy I M Hoepelman; Sangkot Marzuki Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191